Close Menu

multiplex assays

The technologies monitor patient response to immunotherapies. 

Using Luminex's FlexMap detector, the method allows quantification of cells in a mixture of up to hundreds of individual cells lines treated with drugs in vitro.

Bio-Techne is the second firm to sign an instrument distribution deal with Luminex in recent weeks and will continue to develop assays for the Luminex platform.

The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.

The partners will work together to develop serological assays measuring antibodies to determine patient immunity to diseases for which vaccines exist.

The Taiwanese molecular diagnostics firm said the money would be invested in the firm's lineup of oncology assays and used to hire more staff.

Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.

NEW YORK (GenomeWeb) – Nanosphere said after the close of the market Tuesday that the US Food and Drug Administration has granted 510(k) clearance for a part of the firm's Enteric Pathogens Nucleic Acid Test.

NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market Tuesday that it will develop a companion diagnostic test for Celgene's Revlimid (lenalidomide), which the firm is developing for diffuse large B-cell lymphoma.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.